Trying to Reduce Post TAVR Kidney Injury

Acute kidney injury is a common complication after transcatheter aortic valve replacement (TAVR) and is associated to increased mortality both short and long-term. 

Sub análisis del EXCEL: angioplastia vs cirugía en insuficiencia renal crónica

In patients undergoing percutaneous coronary intervention (PCI) forcing diuresis with controlled hydration has shown to reduce the incidence of acute kidney injury in nearly 50%. However, this has not been tested in patients undergoing TAVR.

This single center study, soon to be published in the European Heart Journal, prospectively randomized double-blind patients to test the effect of controlled saline infusion to force diuresis and prevent kidney injury in TAVR patients. 

136 patients were randomized (68 in each group) with mean age 83.9 ± 5 years and no significant differences in baseline characteristics. 


Read also: The Most Read Scientific Articles in September at Solaci.org.


Acute kidney injury rate was no different between the groups (25% active group vs 19.1% controlled group; p=0.408). There was a significant increase in long term mortality in the active group (27.9% vs 13.2%, HR 3.7 CI 95% 1.51 to 9.28; p=0.004), which caused early termination for futility and damage risk.

Conclusion

In contrast with PCI, TAVR does not prevent acute kidney injury and might even be associated to higher mortality. Further study is required to better understand the physiopathology behind these findings. 

Original Title: Forced diuresis with matched hydration during transcatheter aortic valve implantation for Reducing Acute Kidney Injury: a randomized, sham-controlled study (REDUCE-AKI).

Reference: Yaron Arbel et al. European Heart Journal (2019), online before print.



Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...